Immunosuppressive drugs for IBD raise skin cancer risk
Patients with inflammatory bowel disease have a 60% higher risk of developing nonmelanoma skin cancer, mainly stemming from immunosuppressive medication, according to research presented at the ACG annual meeting. The study, which analyzed insurance claims from 87 health plans in 33 states, focused on the use of thiopurines, methotrexate and biologic agents.
MedPage Today | 10/27
This story published in Digestive Health SmartBrief on 10/30/2009
More from SmartBrief:
Study: Accutane users have higher IBD risk
Wednesday, November 4, 2009
Studies differ on prevalence of dyssynergic defecation by gender
Friday, October 30, 2009
Community-based C. difficile infections increasing
Friday, November 6, 2009
Get stories like these delivered daily for FREE:
|
Digestive Health SmartBrief
From the American College of Gastroenterology and its member physicians, Digestive Health SmartBrief is a free, twice-weekly newsletter. It provides news and information for your digestive health, including stories on healthy living, developments in diagnosis and treatment, and important legislation shaping the health care landscape. You'll also find a clinical trial monitor, patient perspectives, and a resource center. Come sign up today. Learn more |
|